3 US Penny Stocks With Market Caps Over $10M To Consider

As investors navigate a mixed market landscape, with major indices showing varied performances amid a wave of earnings reports, the allure of smaller investment opportunities remains significant. Penny stocks, though often associated with speculative trading, still hold potential when backed by robust financials. These companies can offer unique growth prospects and value that larger firms may overlook. In this article, we explore several penny stocks that stand out for their financial strength and potential for long-term success.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8577	$6.52M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$121.59M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2799	$9.75M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.03	$88.27M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.43	$47.85M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$3.09	$51.01M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.35	$21.99M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9234	$83.69M	★★★★★☆
SideChannel (OTCPK:SDCH)	$0.038815	$9.04M	★★★★★★

Click here to see the full list of 706 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Cyclerion Therapeutics (NasdaqCM:CYCN)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious diseases, with a market cap of $13.46 million.

Operations: Cyclerion Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $13.46M

Cyclerion Therapeutics, Inc., a pre-revenue biopharmaceutical company with a market cap of US$13.46 million, recently filed a US$25 million Shelf Registration. Despite its unprofitability and negative return on equity, the company has seen significant reduction in losses over the past five years at an annual rate of 49.4%. However, it faces challenges with less than one year of cash runway and highly volatile share prices. The board is experienced, but management tenure data is insufficient to assess leadership stability fully. Cyclerion remains debt-free with short-term assets exceeding liabilities by US$2.8 million.

• Dive into the specifics of Cyclerion Therapeutics here with our thorough balance sheet health report.
• Explore historical data to track Cyclerion Therapeutics' performance over time in our past results report.

Smart Share Global (NasdaqCM:EM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Smart Share Global Limited is a consumer tech company offering mobile device charging services in the People's Republic of China, with a market cap of $296.92 million.

Operations: The company's revenue is derived from its Rental & Leasing segment, which generated CN¥1.96 billion.

Market Cap: $296.92M

Smart Share Global Limited, with a market cap of $296.92 million, has become profitable recently and shows strong financial health, as its short-term assets (CN¥4 billion) exceed both short- and long-term liabilities. The company is debt-free and has not diluted shareholders over the past year. Its earnings are forecast to grow significantly at 43.55% annually, although its return on equity remains low at 2.3%. Recently, a consortium proposed acquiring an 83.10% stake for approximately $130 million; however, no definitive decisions have been made regarding this transaction's completion or approval.

• Click here to discover the nuances of Smart Share Global with our detailed analytical financial health report.
• Learn about Smart Share Global's future growth trajectory here.

Baozun (NasdaqGS:BZUN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Baozun Inc., with a market cap of $178.94 million, offers comprehensive e-commerce solutions to brand partners in China through its subsidiaries.

Operations: The company's revenue is primarily derived from its E-Commerce segment, which generated CN¥7.93 billion, and its Brand Management segment, contributing CN¥1.40 billion.

Market Cap: $178.94M

Baozun Inc., with a market cap of $178.94 million, is currently unprofitable but has shown some financial resilience. Its short-term assets (CN¥7 billion) comfortably cover both short- and long-term liabilities, and it boasts a sufficient cash runway for over three years. Despite a negative return on equity of -3.18%, Baozun is trading at 73.6% below its estimated fair value, suggesting potential undervaluation compared to peers. The company recently completed a share buyback program but faced delisting from OTC Equity due to inactivity, which may affect investor sentiment moving forward.

• Click here and access our complete financial health analysis report to understand the dynamics of Baozun.
• Examine Baozun's earnings growth report to understand how analysts expect it to perform.

Taking Advantage

• Click through to start exploring the rest of the 703 US Penny Stocks now.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com